Edgewood Oncology
Private Company
Funding information not available
Overview
Edgewood Oncology is a private, clinical-stage biotech based in San Diego, advancing its lead asset BTX-A51, a first-in-class, multi-specific inhibitor of CK1α, CDK7, and CDK9. The compound has shown promising early clinical activity and a favorable safety profile in Phase 1 studies in AML and solid tumors, and is now being explored in investigator-sponsored studies for liposarcoma. The company's strategy focuses on genetically-defined cancers, leveraging a novel mechanism that indirectly inhibits key survival proteins like MDM2 and MCL-1 to activate p53 and apoptosis.
Technology Platform
BTX-A51, a novel small molecule multi-specific inhibitor of CK1α, CDK7, and CDK9, designed to synergistically target master regulators of cancer (p53, super-enhancers) to induce apoptosis with a potentially favorable safety profile compared to direct inhibitors.
Opportunities
Risk Factors
Competitive Landscape
Edgewood competes in the crowded oncology kinase inhibitor space, specifically against companies developing direct CDK7 inhibitors (e.g., Syros Pharmaceuticals), CDK9 inhibitors, MDM2 inhibitors (e.g., Sanofi, Roche), and MCL-1 inhibitors (e.g., AstraZeneca, Amgen). Its key differentiation is the synergistic triple-inhibition approach and an indirect mechanism aimed at avoiding the dose-limiting toxicities seen with direct inhibitors.